Method for producing pyrone and pyridone derivatives
AssigneeShionogi & Co., Ltd.
InventorsYukihito Sumino, Kazuya Okamoto, Moriyasu Masui, Toshiyuki Akiyama
Life of this patent
Estimating the term…
Abstract
The present invention provides a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug, a method of producing the same, and a method of using the same.
Claims11
1-18. (canceled)
A method of producing a compound shown by formula (X3) or formula (XA3), or a salt thereof:
- wherein
- R1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3,
- R1es are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E or heterocyclyl lower alkyl optionally substituted by substituent E,
- R2d is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
- comprising reacting a compound shown by formula (X2):
- wherein:
- R3d is hydrogen, lower alkyl optionally substituted by substituent E, N(R3e)2, or —OR3e,
- R3es are each independently lower alkyl optionally substituted by substituent E, or may be taken together to form a heterocycle;
- Substituent E:
- halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio optionally substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocyclylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulfonylamino;
- Substituent F:
- halogen, hydroxy, carboxy, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, and amino protective group);
- and
- wavy line is E form and/or Z form or the mixture thereof;
- with a compound shown by formula (V2) or formula (VA2):
- wherein
- R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
- R4es are each independently hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, or heterocyclyl optionally substituted by substituent E,
- R5d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO2—R5e,
- R5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E and
- substituent E is defined above.
A compound shown by formula (X3), or a pharmaceutically acceptable salt thereof or solvate thereof:
- wherein
- R1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3,
- R1es are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E or heterocyclyl lower alkyl optionally substituted by substituent E,
- R2d is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
- R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
- Substituent E:
- halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio optionally substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocyclylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulfonylamino:
- Substituent F:
- halogen, hydroxy, carboxy, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, and amino protective group);
- and
- wavy line is E form and/or Z form or the mixture thereof;
- with a compound shown by formula (V2) or formula (VA2):
- wherein
- R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
- R4es are each independently hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, or heterocyclyl optionally substituted by substituent E,
- R5d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO2—R5e,
- R5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E and
- substituent E is defined above.
A crystal of a compound shown by formula (1D) or a solvate thereof:
- (wherein Me is a methyl group, and Bn is a benzyl group),
- wherein the compound has a peak at a diffraction angle (2θ):
- 7.9°±0.2°, 10.0°±0.2°, 11.5°±0.2°, 20.0°±0.2°, 23.4°±0.2° and 34.0°±0.2° in a powder X-ray diffraction spectrum.
A crystal of a compound represented by formula (2D) or a solvate thereof:
- (wherein Me is a methyl group, Et is an ethyl group, and Bn is a benzyl group), wherein the compound has a peak at a diffraction angle (2θ):
- 17.6°±0.2°, 25.2°±0.2°, 26.4°±0.2° and 28.1°±0.2° in a powder X-ray diffraction spectrum.
A crystal of a compound shown by formula (9C′) or a solvate thereof:
- (wherein Me is a methyl group, and Bn is a benzyl group),
- wherein the compound has a peak at a diffraction angle (2θ):
- 14.2°±0.2°, 16.0°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 24.4°±0.2° and 25.9°±0.2° in a powder X-ray diffraction spectrum.
Dependencies are inferred from the claim text.